KRIBIOLISA Dasatinib (SPRYCEL) ELISA

Enzyme Immunoassay for the quantitative determination of Dasatinib in serum, plasma and cell culture supernatant Dasatinib, sold under the brand name Sprycel, is a targeted therapy used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+). It is taken by orally. About the kit: - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Ready to use with a standard protocol with break-apart pre-coated wells - Validated as per US FDA guidelines for Bioassays - Optimized for matrix effects to ensure higher sensitivity. - Shelf life: 1 year The Dasatinib ELISA is a competitive immunoassay for the determination of Dasatinib. A constant concentration of Tracer; varying concentrations of unlabeled standard and BCR-ABL Tyrosine Kinase are added in sequence to the uncoated microtitre plate wells and incubated. After 1st incubation, Anti- (BCR-ABL Tyrosine Kinase) Antibody is dispensed to all wells of uncoated Microtitre plate containing the reaction mixture and incubated. After 2nd incubation, all reaction mixtures are transferred to the respective wells of coated microtitre plate and incubated. After washing, Streptavidin HRP conjugate is added and incubated. Captured Tracer is subsequently bound by streptavidin HRP which produces a soluble colored product after addition of TMB substrate. The enzyme reaction is stopped by dispensing of stop solution into the wells.The optical density (OD) of the solution at 450 nm is inversely proportional to the amount of bound Dasatinib molecule present in standards or samples.